BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival. Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse. No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia. DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available. The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemia patients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy. RESULTS: Twenty of the 238 patients analyzed had WT1 mutations (WT1mut) in exon 7. WT1mut cases were characterized by immature features such as an early immunophenotype and higher WT1 expression. In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients. T-lymphoblastic leukemia patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression. In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression. In multivariate analysis, WT1 expression was of independent prognostic significance for relapse-free survival. CONCLUSIONS: WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemia patients. Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.
BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival. Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse. No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia. DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available. The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemiapatients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy. RESULTS: Twenty of the 238 patients analyzed had WT1 mutations (WT1mut) in exon 7. WT1mut cases were characterized by immature features such as an early immunophenotype and higher WT1 expression. In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients. T-lymphoblastic leukemiapatients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression. In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression. In multivariate analysis, WT1 expression was of independent prognostic significance for relapse-free survival. CONCLUSIONS:WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemiapatients. Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.
Authors: Pieter Van Vlierberghe; Jules P P Meijerink; Ronald W Stam; Wendy van der Smissen; Elisabeth R van Wering; H Berna Beverloo; Rob Pieters Journal: Blood Date: 2005-12-15 Impact factor: 22.113
Authors: K Ito; Y Oji; N Tatsumi; S Shimizu; Y Kanai; T Nakazawa; M Asada; T Jomgeow; S Aoyagi; Y Nakano; H Tamaki; N Sakaguchi; T Shirakata; S Nishida; M Kawakami; A Tsuboi; Y Oka; Y Tsujimoto; H Sugiyama Journal: Oncogene Date: 2006-03-06 Impact factor: 9.867
Authors: Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando Journal: Blood Date: 2009-06-03 Impact factor: 22.113
Authors: E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert Journal: Leukemia Date: 2003-12 Impact factor: 11.528
Authors: Andrea Kühnl; Martin Kaiser; Martin Neumann; Lars Fransecky; Sandra Heesch; Michael Radmacher; Guido Marcucci; Clara D Bloomfield; Wolf-Karsten Hofmann; Eckhard Thiel; Claudia D Baldus Journal: Leuk Res Date: 2011-09-06 Impact factor: 3.156
Authors: Anne-Sophie Junghanns; Susan Wittig; Caroline Woehlecke; Thomas Lehmann; Clemens Arndt; Bernd Gruhn Journal: J Cancer Res Clin Oncol Date: 2015-07-30 Impact factor: 4.553
Authors: Zsófia Ujj; Gergely Buglyó; Miklós Udvardy; György Vargha; Sándor Biró; László Rejtő Journal: Pathol Oncol Res Date: 2013-12-28 Impact factor: 3.201
Authors: M Neumann; S Heesch; N Gökbuget; S Schwartz; C Schlee; O Benlasfer; N Farhadi-Sartangi; J Thibaut; T Burmeister; D Hoelzer; W-K Hofmann; E Thiel; C D Baldus Journal: Blood Cancer J Date: 2012-01-27 Impact factor: 11.037
Authors: Martin Neumann; Sebastian Vosberg; Cornelia Schlee; Sandra Heesch; Stefan Schwartz; Nicola Gökbuget; Dieter Hoelzer; Alexander Graf; Stefan Krebs; Isabelle Bartram; Helmut Blum; Monika Brüggemann; Jochen Hecht; Stefan K Bohlander; Philipp A Greif; Claudia D Baldus Journal: Oncotarget Date: 2015-02-20